logo
Share SHARE
FONT-SIZE Plus   Neg

WuXi PharmaTech Q1 Results Top View; Backs 2012 Outlook

Chinese research and development outsourcing company WuXi PharmaTech (Cayman), Inc. (WX) reported Thursday a profit for the first quarter that increased from last year, reflecting strong double-digit revenue growth, despite lower margins.

Both adjusted earnings per share and quarterly revenues topped analysts' expectation. The company also provided revenue guidance for the second quarter, above Street view, and reaffirmed revenue forecast for the full-year 2012.

"WuXi began 2012 with a strong first quarter, achieving 26.2% revenue growth. This strong revenue growth was broad-based across all of our businesses. We met or exceeded all of our financial targets for revenues and margins for the quarter," Chairman and CEO Dr. Ge Li said in a statement.

The Shanghai, China-based company reported net income of $20.99 million or $0.28 per ADS for the first quarter, higher than $18.22 million or $0.24 per ADS in the prior-year quarter.

Excluding items, adjusted net income for the quarter increased about15 percent to $24.47 million or $0.33 per ADS from $21.38 million or $0.29 per ADS in the year-ago quarter.

On average, four analysts polled by Thomson Reuters expected the company to earn $0.27 per share for the quarter. Analysts estimates typically exclude special items.

Total net revenues for the quarter increased 26.2 percent to $118.03 million from $93.56 million in same quarter last year, and topped nine Wall Street analysts' consensus estimate of $114.20 million.

Laboratory services net revenues grew 23.2 percent to $86.6 million, with China-based revenues growing 25.8 percent and U.S.-based revenues increasing 16.4 percent. Manufacturing services net revenues rose 35.0 percent to $31.4 million from last year.

"China is becoming an important hub for pharmaceutical R&D in part because of China's pharmaceutical market, already the third largest in the world and growing very rapidly. By building high-quality operations to better serve our customers, WuXi has become the leader in the Chinese pharmaceutical R&D services industry," Li added.

Operating margin declined 370 basis points to 17.5 percent, reflecting a 160 basis points decline in gross margin and higher operating expenses.

Looking ahead to the second quarter, the company expects total revenues in a range of $124 million to $129 million, with analysts estimating revenues of $118.03 million.

For fiscal 2011, the company continues to expect total net revenues between $468 million and $488 million, with Street currently looking for full-year revenues of $477.62 million.

"We are well-positioned to take full advantage of the significant long-term trend for increasing outsourcing of pharmaceutical research and development," Li said.

WX closed Thursday's regular trading session at $13.41, down $0.21 or 1.54% on a volume of 0.41 million shares. However, the stock gained $0.59 or 4.40% in after-hours trading.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
RELATED NEWS
Trade WX now with 
Follow RTT